Codex DNA, which makes an automated synthetic biology workstation and related solutions, filed on Friday with the SEC to raise up to $100 million in an initial public offering.
Codex DNA states that its synthetic biology solution addresses the bottlenecks across the multi-step process of building DNA and mRNA. A key part of its solution is its BioXp system, an end-to-end automated workstation that fits on the benchtop and provides ease-of-use and hands-free automation. The company commercially launched its current synthetic biology solution in September 2019, which now includes the BioXp 3250 system, BioXp kits with associated cloud-based application scripts, and benchtop reagent kits.
The San Diego, CA-based company was founded in 2011 and booked $8 million in sales for the 12 months ended March 31, 2021. It plans to list on the Nasdaq under the symbol DNAY. Codex DNA filed confidentially on March 16, 2021. Jefferies, Cowen, and KeyBanc Capital Markets are the joint bookrunners on the deal. No pricing terms were disclosed.
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.